Celgene News

A donation by a North Jersey biopharmaceutical company will help ease the burden of blood cancer patients in need of financial assistance.

This drove us to do research on the following 6 stocks Hemispherx Biopharma Inc.

Celgene saw some unexpected stock activity Friday morning after the company announced results from a late-stage study of its cancer drug Revlimid.

Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 10 a.m. in New York.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Wholesale Sales m/m for Oct was released in Canada; the outcome was -1.5% losing 1.6 from the prior reading of 0.1%, - less than expectations of 0.3%. The Dow Jones Industrial Average advanced +20.63 points to 10328.89 points.

Dallas, TX - Cell Therapeutics, Inc. surged 8.57% to $1.14 on 47.57 million shares.

Filed under: Major movement , Good news , Options , Technical Analysis Celgene shares are rising today after a late-stage study of its blood cancer drug Revlimid was found to be so effective that the study was stopped early .

Drug stocks gained ground Friday, as shares of Celgene Inc. jumped on a positive clinical study and Sanofi shares rose on a favorable outlook for its vaccines business.

Celgene Corp. said Friday data from a late-stage study show Revlimid significantly slowed the progression of multiple myeloma in patients following a type of stem cell treatment.

Celgene Corporation today announced the National Cancer Institute , a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B . The investigational study evaluated REVLIMID compared to placebo in multiple myeloma patients ...

From Associated Press SUMMIT, N.J.--Biotechnology company Celgene Corp. said Tuesday its experimental psoriasis treatment, apremilast , met key goals in a midstage clinical trial.

Mr. Bocek brings over 20 year... SUMMIT, N.J.-- --Celgene Corporation announced the election of Carrie S. Cox to the Company's Board of Directors.

EntreMed Inc. had severely overestimated the amount of revenue it planned on receiving in royalty payments for the third quarter this year, a revelation that could turn a slight quarterly profit into a $1.5 million loss.

Celgene Corp. recently disclosed that its drug candidate, apremilast, for treating patients with moderate-to-severe plaque-type psoriasis, met key goals in a mid-stage study .

Biotechnology company Celgene Corp. said Tuesday its experimental psoriasis treatment, apremilast, met key goals in a midstage clinical trial.

Dec 15, 2009 - Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast in patients with moderate-to-severe plaque-type psoriasis .

With Monday's acquisition of Gloucester Pharmaceuticals , Celgene will soon launch Istodax as a treatment for cutaneous T-cell lymphoma .

It was shaping up to be a fight amongst the little guys. In September, Allos Therapeutics received Food and Drug Administration approval for Folotyn to treat peripheral T-cell lymphoma , and last month, privately held Gloucester Pharmaceuticals got Istodax approved to treat related cutaneous T-cell lymphoma .

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.